TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. - Wikidata - wikimedia - TriplyDB

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

http://www.wikidata.org/entity/Q27851621

about

The epigenetic landscape of acute myeloid leukemia Epigenetic regulators and their impact on therapy in acute myeloid leukemia Acute Myeloid Leukemia: A Concise Review Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid Leukemia Molecular Genetic Markers in Acute Myeloid Leukemia Volasertib for AML: clinical use and patient consideration Post-remission therapy for acute myeloid leukemia Molecular prognostic factors in cytogenetically normal acute myeloid leukemia Myeloid malignancies: mutations, models and management CIViC database Next generation sequencing of acute myeloid leukemia: influencing prognosis.ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation Epigenetic Guardian: A Review of the DNA Methyltransferase DNMT3A in Acute Myeloid Leukaemia and Clonal Haematopoiesis.Significance of oncogenes and tumor suppressor genes in AML prognosis.Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.TET2 binds the androgen receptor and loss is associated with prostate cancer.TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population.Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.Integrated analysis of germline and somatic variants in ovarian cancer.GAS6 expression identifies high-risk adult AML patients: potential implications for therapy Molecular therapy for acute myeloid leukaemia.Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia.Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion.Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.Expression and prognostic impact of lncRNAs in acute myeloid leukemia.TET proteins and the control of cytosine demethylation in cancer.Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

P2860

b5d3da32b617caf3881245951a2e9e20206dc54f

P248

Q21284742-40F693A9-12B1-409A-A907-7413109E5FD8 Q26765402-182B6C54-0103-4F37-8334-C34FB369FDCF Q26766719-C61765A6-6F0C-43A3-B0C9-F35B92818A77 Q26770391-2A314FA8-5B22-42A7-8B86-86583D59EDB5 Q26796514-6D063AD9-2CDB-4222-A2B0-507E44FCCC1D Q26799606-69161254-E5D8-40FC-B612-5B0938D13367 Q26801131-2B558824-5140-45AE-95B8-1525552113D8 Q26995867-F0892FEE-8EE2-4C28-9DA5-CFCEB3DD0A72 Q26998811-AFDFFE50-3FCC-4801-9CAB-81BC757DCE79 Q27000577-F7AD7674-7ACF-4181-8529-D0CD7AE32A27 Q27612411-8E7E935D-EB9B-45DB-AAF4-40BC897206B0 Q27690776-058AF79F-EB4B-4A70-BD59-0CBDB7770D42 Q27851679-131D2256-5C34-4AA6-8FC8-CC3319AFC054 Q27851689-DFC6C898-F1DF-42B7-99C9-D67636675418 Q27851694-01036CE3-CCF5-4010-AE1A-310E04D7F539 Q27851713-096802F0-D7C7-4A80-8B0E-FE9058BC964F Q27851726-107A26EC-650F-40A1-869A-E762ED28A847 Q27851839-6BA9E27A-FE4C-4267-A924-C18606BAD90E Q27853009-50168E3B-2732-434E-B328-8AAF0A1B8CE9 Q28075654-4955B94C-4049-4E30-B417-6D42DCD1D73F Q28508217-41078073-EF94-4667-AADF-6D18073DEB58 Q30235316-D679AA4D-6D8E-4A57-A253-FC0E175022A1 Q30250315-01C1152E-414A-4E4D-971A-8E870123F0AF Q30449092-7C9B62DC-0156-4BFD-9A5B-3AEEE6A26F7D Q33563729-F5AF550F-87BC-461D-9CDB-8DFDB39E4B84 Q33566938-9A6BC3FB-682A-4514-B672-D7E716D6E1D3 Q33583033-90C737E0-FA9C-4876-B97F-959DF63F2E14 Q33630954-D0305FF1-FFAD-4C47-AEF6-7D89A64292D6 Q33717707-8EF11F5A-11CD-4D21-A9AE-313B1D0B3968 Q33925672-C9FA293C-A3AB-4911-842E-96E8789544E3 Q34347096-668BBD28-A7C1-4D34-B085-E889F45B38FC Q34388734-0CC6F939-4986-458B-A0BE-5BE76BD92706 Q34443734-8345F468-EB82-4945-A715-FD895E82A7B9 Q34651312-30DEFB40-EFBC-43A7-A376-996DEDDDA0F7 Q34831106-ECF177C6-B0EA-4A80-AA09-B44DE7528FC6 Q35021377-4E4AD21B-C198-4DE6-837E-EA238E718A0D Q35049985-760B3EAD-49C8-459E-B110-676F4D7AE31E Q35132953-7AB753E6-001C-4195-9DE9-8350399B0F41 Q35152173-ACD316A7-B637-49A9-853D-9F4325724B48 Q35265946-04B1BA1B-277E-4E92-9FC5-0D24F4FD803D

P2860

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

http://www.wikidata.org/entity/Q27851621

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

TET2 mutations improve the new ...... er and Leukemia Group B study.

@ast

TET2 mutations improve the new ...... er and Leukemia Group B study.

@en

TET2 mutations improve the new ...... er and Leukemia Group B study.

@nl

type

label

TET2 mutations improve the new ...... er and Leukemia Group B study.

@ast

TET2 mutations improve the new ...... er and Leukemia Group B study.

@en

TET2 mutations improve the new ...... er and Leukemia Group B study.

@nl

altLabel

TET2 Mutations Improve the New ...... cer and Leukemia Group B Study

@en

prefLabel

TET2 mutations improve the new ...... er and Leukemia Group B study.

@ast

TET2 mutations improve the new ...... er and Leukemia Group B study.

@en

TET2 mutations improve the new ...... er and Leukemia Group B study.

@nl

P1433

Q27851621-6E9C6241-D377-4C42-85F6-D62F22B743FA

P1476

Q27851621-76F4A43C-D778-4165-9729-D5B8F4F0A30E

P2093

Q27851621-3759A039-4C30-41A0-8104-47B882F4A5FE

Q27851621-38A55E0C-D7F3-47D3-81A5-C791F7F3EFAA

Q27851621-518733C1-1498-4B2A-85DB-6C9F1FA65AC4

Q27851621-5AB82183-E94C-4ED0-AAB6-C69D01F14A01

Q27851621-5E187053-1046-41B3-85F1-A43AEAD96F9A

Q27851621-61E4E8DF-6D40-4F3B-B430-80551589A600

Q27851621-83A21052-3809-4BA7-98F3-6A2B94A39C12

Q27851621-939FF9CF-B477-419D-BC83-B9F52B838CFE

Q27851621-949EA7EB-A85C-4D40-A697-6E6A0978C9F6

Q27851621-A9C0931D-6E17-4752-9FC4-F3E5B426CF22

P2860

Q27851621-06BE3A71-BC6B-458E-8CC1-F7267B730BFA

Q27851621-0B8BF094-41AB-41A8-9BF7-D28559457917

Q27851621-0D3B12C3-F0C6-430D-8388-48231987C530

Q27851621-13FC570E-7FA7-4312-B0E2-FA0DA6273634

Q27851621-1C638174-C659-468D-8B08-B5A3BC1B1803

Q27851621-2577CD7E-D9FE-4143-BC6D-391A58476BA3

Q27851621-291FD548-3132-4DEA-B4DA-CC8F3BCFE7E6

Q27851621-2C608468-FC3A-4754-88AC-080C15E118FB

Q27851621-2CB53A7A-6953-40A1-9230-107A0C171221

Q27851621-2D964D2F-CBDD-43CC-9AEA-2DB389A0449A

P304

Q27851621-79FB43C0-F8D2-42B8-8286-650F97C720AC

P31

Q27851621-8204390C-7B81-4EDE-A344-010D32EE7C9B

P3181

Q27851621-8B521E3E-E23B-4E28-9666-09B70B1AE792

P356

Q27851621-083ACDC0-318A-4B4B-9E23-16F52F45737C

P407

Q27851621-F06D4D64-AA90-42D8-AC69-04B5355344CA

P433

Q27851621-463D4B2F-A758-45A4-A021-5F9FDEB5294F

P478

Q27851621-3F606239-D5F2-4F38-B758-AA4DA9305046

P50

Q27851621-02918887-C940-477B-8861-BCB594C7E6C1

Q27851621-1308644C-09E4-40B4-8A66-3E461C6D87E8

Q27851621-1BB79217-6210-4C0F-B31C-3A8CB55FF32A

Q27851621-2C688223-4DB9-442D-ABF6-49F39FAB3F2E

Q27851621-592767DF-6944-468D-A9DE-4D98F0DB4C6A

Q27851621-5D4C4F65-6DB5-4687-97D6-D024E5D0C613

Q27851621-C8DF90A9-9B43-4C0C-A965-7B7E8AF5DFA8

P577

Q27851621-3A67747F-2ECE-4A7F-95BA-372F1D7D91B6

P698

Q27851621-F2B023E7-4F63-4133-8B48-270C142273BF

P921

Q27851621-2DBD565A-AFCA-4EAE-8A5F-C1DE282BED6C

P932

Q27851621-AF86299E-0D8B-4EA2-8727-B09E5FD04D2E

P3181

P356

JCO.2010.32.7742

P1433

Journal of Clinical Oncology

P1476

TET2 mutations improve the new ...... er and Leukemia Group B study.

@en

P2093

Andrew J Carroll

http://www.w3.org/2001/XMLSchema#string

Bayard L Powell

http://www.w3.org/2001/XMLSchema#string

Dean Margeson

http://www.w3.org/2001/XMLSchema#string

Heiko Becker

http://www.w3.org/2001/XMLSchema#string

John Curfman

http://www.w3.org/2001/XMLSchema#string

Jonathan E Kolitz

http://www.w3.org/2001/XMLSchema#string

Joseph O Moore

http://www.w3.org/2001/XMLSchema#string

Kelsi B Holland

http://www.w3.org/2001/XMLSchema#string

Maria R Baer

http://www.w3.org/2001/XMLSchema#string

Meir Wetzler

http://www.w3.org/2001/XMLSchema#string

P2860

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

Human HTm4 is a hematopoietic cell cycle regulator

dbSNP: the NCBI database of genetic variation

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

P304

1373-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2457924

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2010.32.7742

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Klaus H Metzeler

Richard A. Larson

Clara D. Bloomfield

Krzysztof Mrózek

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21343549

http://www.w3.org/2001/XMLSchema#string

P921

P932

3084003

http://www.w3.org/2001/XMLSchema#string